Voyager Acquisition Corp (VACH) is a forward-thinking special purpose acquisition company (SPAC) committed to identifying and merging with innovative technology firms that are leading the charge in digital transformation and sustainability. With a seasoned management team that possesses substantial expertise in finance and operational integration, VACH strategically targets high-growth opportunities within the fast-evolving tech landscape. As the appetite for cutting-edge technological solutions intensifies, Voyager is well-positioned to establish transformative partnerships that are likely to enhance shareholder value and leverage emerging market trends effectively.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.87% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.42 |
| Price-to-Book | 1.36 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | -91.10% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $25.30M |
| Float | 82,660 |
| % Insiders | 1.08% |
| % Institutions | 10.46% |
Volatility is currently expanding
The business combination of VERAXA Biotech and Voyager Acquisition Corp. was closed successfully and NASDAQ trading of $VRXA commences on June 11, 2026.
VERAXA Biotech AG has strengthened its financial position to position to support the closing of its business combination with Voyager Acquisition Corp.
